Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.53 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3934056 | 0.86 | FAAH (0.47) | FAAHALDH1A1 | |
| SCHEMBL9191664 | 0.85 | KDM4E (0.46) | FAAHTAAR1ALDH1A1 | |
| SCHEMBL27920227 | 0.83 | TAAR1 (0.62) | TAAR1ACHE | |
| SCHEMBL13454202 | 0.83 | FAAH (0.43) | FAAHTAAR1ALDH1A1 | |
| SCHEMBL28747906 | 0.83 | FAAH (0.43) | FAAHTAAR1ALDH1A1 | |
| SCHEMBL6937296 | 0.82 | CYP4F2 (0.55) | CYP4F2CYP4A11TDP1 | |
| SCHEMBL8000451 | 0.82 | FAAH (0.42) | FAAHTAAR1ALDH1A1 | |
| SCHEMBL5991853 | 0.81 | FAAH (0.42) | FAAHMTNR1AMTNR1B | |
| SCHEMBL3169174 | 0.81 | SOD1 (0.45) | FAAHALDH1A1TDP1 | |
| SCHEMBL10179751 | 0.81 | PPARA (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925182-B2 | Compositions, dosage forms, and co-administration of an opioid agonist compound and an analgesic compound | NEKTAR THERAPEUTICS (US) | 2018-03-27 | — | — | US | disclosed |
| US-9827239-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2017-04-27 | — | — | US | disclosed |
| US-20170079975-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | NEKTAR THERAPEUTICS | 2017-03-23 | — | — | US | disclosed |
| US-9512135-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-12-06 | — | — | US | disclosed |
| US-9458166-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-10-04 | — | — | US | disclosed |
| US-9457024-B2 | Compositions, dosage forms, and co-administration of an opioid agonist compound and a non-steroidal anti-inflammatory drug | NEKTAR THERAPEUTICS | 2016-10-04 | — | — | US | disclosed |
| US-20160130276-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS | 2016-05-12 | — | — | US | disclosed |
| US-9233167-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-12 | — | — | US | disclosed |
| CN-105008378-A | Reaction catalyst for cross coupling and method for manufacturing aromatic compound | HOKKO CHEM IND CO | 2015-10-28 | — | — | CN | disclosed |
| US-8569343-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-10-29 | — | — | US | disclosed |
| US-8440687-B2 | Oligomer-opioid agonist conjugates | NEKTAR THERAPEUTICS (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | NEKTAR THERAPEUTICS (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | NEKTAR THERAPEUTICS (US) | 2012-10-18 | — | — | US | disclosed |
| EP-1167372-B1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO PERFUMERY CO LTD (JP) | 2003-12-10 | — | — | EP | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| US-6365776-B1 | FROM ORGANOHALOGEN COMPOUND AND AMINE USING PALLADIUM COMPOUND CATALYST AND PROMOTER | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-04-02 | — | — | US | disclosed |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TAKASAGO INTERNATIONAL CORPORATION | 2002-03-21 | — | — | US | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112826-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | CYP4F2 1215/4885CYP4A11 729/4885FAAH 803/4885 |
| US-20020035295-A1 | PROCESS FOR PRODUCING AROMATIC AMINES | TYR, DDC, PNMT | CYP4F2 1291/4885CYP4A11 1062/4885FAAH 2616/4885 |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | CYP4F2 2326/4885CYP4A11 3474/4885FAAH 2066/4885 |
| US-20170079975-A1 | Compositions, Dosage Forms, and Co-Administration of an Opioid Agonist Compound and an Analgesic Compound | OPRL1, OPRM1, OPRK1 | CYP4F2 874/4885CYP4A11 183/4885FAAH 282/4885 |
| US-20160130276-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | CYP4F2 1215/4885CYP4A11 729/4885FAAH 803/4885 |
| US-20120289548-A1 | OLIGOMER-OPIOID AGONIST CONJUGATES | OPRM1, OPRL1, OPRK1 | CYP4F2 1215/4885CYP4A11 729/4885FAAH 803/4885 |
| US-20120264775-A1 | Oligomer-Opioid Agonist Conjugates | OPRM1, OPRL1, OPRK1 | CYP4F2 1215/4885CYP4A11 729/4885FAAH 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.